360 related articles for article (PubMed ID: 26523267)
1. The mutational landscape of hepatocellular carcinoma.
Lee JS
Clin Mol Hepatol; 2015 Sep; 21(3):220-9. PubMed ID: 26523267
[TBL] [Abstract][Full Text] [Related]
2. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections.
Tornesello ML; Buonaguro L; Tatangelo F; Botti G; Izzo F; Buonaguro FM
Genomics; 2013 Aug; 102(2):74-83. PubMed ID: 23583669
[TBL] [Abstract][Full Text] [Related]
3. The genomic landscape of hepatoblastoma and their progenies with HCC-like features.
Eichenmüller M; Trippel F; Kreuder M; Beck A; Schwarzmayr T; Häberle B; Cairo S; Leuschner I; von Schweinitz D; Strom TM; Kappler R
J Hepatol; 2014 Dec; 61(6):1312-20. PubMed ID: 25135868
[TBL] [Abstract][Full Text] [Related]
4. Next generation sequencing reveals genetic landscape of hepatocellular carcinomas.
Li S; Mao M
Cancer Lett; 2013 Nov; 340(2):247-53. PubMed ID: 23063663
[TBL] [Abstract][Full Text] [Related]
5. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
[TBL] [Abstract][Full Text] [Related]
6. Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma.
Torrecilla S; Sia D; Harrington AN; Zhang Z; Cabellos L; Cornella H; Moeini A; Camprecios G; Leow WQ; Fiel MI; Hao K; Bassaganyas L; Mahajan M; Thung SN; Villanueva A; Florman S; Schwartz ME; Llovet JM
J Hepatol; 2017 Dec; 67(6):1222-1231. PubMed ID: 28843658
[TBL] [Abstract][Full Text] [Related]
7. Integrative analysis reveals novel driver genes and molecular subclasses of hepatocellular carcinoma.
Yang L; Zhang Z; Sun Y; Pang S; Yao Q; Lin P; Cheng J; Li J; Ding G; Hui L; Li Y; Li H
Aging (Albany NY); 2020 Nov; 12(23):23849-23871. PubMed ID: 33221766
[TBL] [Abstract][Full Text] [Related]
8. Genetic alterations in hepatocellular carcinoma: An update.
Niu ZS; Niu XJ; Wang WH
World J Gastroenterol; 2016 Nov; 22(41):9069-9095. PubMed ID: 27895396
[TBL] [Abstract][Full Text] [Related]
9. Improvement in the Current Therapies for Hepatocellular Carcinoma Using a Systems Medicine Approach.
Ozcan M; Altay O; Lam S; Turkez H; Aksoy Y; Nielsen J; Uhlen M; Boren J; Mardinoglu A
Adv Biosyst; 2020 Jun; 4(6):e2000030. PubMed ID: 32529800
[TBL] [Abstract][Full Text] [Related]
10. Multiregional whole-genome sequencing of hepatocellular carcinoma with nodule-in-nodule appearance reveals stepwise cancer evolution.
Takeda H; Takai A; Kumagai K; Iguchi E; Arasawa S; Eso Y; Shimizu T; Ueda Y; Taura K; Uemoto S; Kita R; Haga H; Marusawa H; Fujimoto A; Seno H
J Pathol; 2020 Dec; 252(4):398-410. PubMed ID: 32815153
[TBL] [Abstract][Full Text] [Related]
11. Characterization of pediatric hepatocellular carcinoma reveals genomic heterogeneity and diverse signaling pathway activation.
Haines K; Sarabia SF; Alvarez KR; Tomlinson G; Vasudevan SA; Heczey AA; Roy A; Finegold MJ; Parsons DW; Plon SE; López-Terrada D
Pediatr Blood Cancer; 2019 Jul; 66(7):e27745. PubMed ID: 30977242
[TBL] [Abstract][Full Text] [Related]
12. TERT promoter mutations in primary liver tumors.
Nault JC; Zucman-Rossi J
Clin Res Hepatol Gastroenterol; 2016 Feb; 40(1):9-14. PubMed ID: 26336998
[TBL] [Abstract][Full Text] [Related]
13. A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma.
Labgaa I; Villacorta-Martin C; D'Avola D; Craig AJ; von Felden J; Martins-Filho SN; Sia D; Stueck A; Ward SC; Fiel MI; Mahajan M; Tabrizian P; Thung SN; Ang C; Friedman SL; Llovet JM; Schwartz M; Villanueva A
Oncogene; 2018 Jul; 37(27):3740-3752. PubMed ID: 29628508
[TBL] [Abstract][Full Text] [Related]
14. Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89.
Chen GG; Merchant JL; Lai PB; Ho RL; Hu X; Okada M; Huang SF; Chui AK; Law DJ; Li YG; Lau WY; Li AK
Am J Pathol; 2003 Jun; 162(6):1823-9. PubMed ID: 12759240
[TBL] [Abstract][Full Text] [Related]
15. MDM2-p53 pathway in hepatocellular carcinoma.
Meng X; Franklin DA; Dong J; Zhang Y
Cancer Res; 2014 Dec; 74(24):7161-7. PubMed ID: 25477334
[TBL] [Abstract][Full Text] [Related]
16. Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.
Wang K; Lim HY; Shi S; Lee J; Deng S; Xie T; Zhu Z; Wang Y; Pocalyko D; Yang WJ; Rejto PA; Mao M; Park CK; Xu J
Hepatology; 2013 Aug; 58(2):706-17. PubMed ID: 23505090
[TBL] [Abstract][Full Text] [Related]
17. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer.
Hussain SP; Schwank J; Staib F; Wang XW; Harris CC
Oncogene; 2007 Apr; 26(15):2166-76. PubMed ID: 17401425
[TBL] [Abstract][Full Text] [Related]
18. Hepatic aflatoxin B1-DNA adducts and TP53 mutations in patients with hepatocellular carcinoma despite low exposure to aflatoxin B1 in southern Japan.
Shirabe K; Toshima T; Taketomi A; Taguchi K; Yoshizumi T; Uchiyama H; Harimoto N; Kajiyama K; Egashira A; Maehara Y
Liver Int; 2011 Oct; 31(9):1366-72. PubMed ID: 21745313
[TBL] [Abstract][Full Text] [Related]
19. Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy.
Dhanasekaran R; Nault JC; Roberts LR; Zucman-Rossi J
Gastroenterology; 2019 Jan; 156(2):492-509. PubMed ID: 30404026
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive genome sequencing of the liver cancer genome.
Nakagawa H; Shibata T
Cancer Lett; 2013 Nov; 340(2):234-40. PubMed ID: 23142287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
